ATEC — Alphatec Holdings, Inc.

Is ATEC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Alphatec Holdings, Inc. (ATEC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $6.78. The rating moved from Strong Oversold to Oversold on November 7, 2026.

See all oversold Healthcare stocks →

AI analysis

Alphatec Holdings, Inc. (ATEC) is a small‑cap spinal device company whose near‑term performance hinges on continued surgical adoption and disciplined cash management. Revenue growth potential exists through share gains in targeted procedures and any successful new product rollouts, but the balance sheet and ongoing need for capital are the primary constraints. Competitive dynamics and hospital purchasing cycles create meaningful execution risk. Market sentiment toward growth and risk assets could produce short-term upside on positive commercial or clinical news, while financing or clinical setbacks would likely pressure the share price.

Key factors

  • Alphatec Holdings, Inc. (ATEC) operates in a specialized spinal‑surgery/device niche with products tied to procedure volumes and hospital purchasing cycles
  • Commercial traction and adoption curves for surgical implants are the primary drivers of near‑term revenue growth
  • Liquidity and balance‑sheet position constrain runway and increase the likelihood of financing or dilution absent sustained free cash flow
  • Competitive pressure from large orthopedics and medtech firms limits pricing power and share gains in key hospital accounts
  • Sector sentiment is modestly constructive for risk assets, which can support episodic rallies on positive results or product adoption
  • Execution on supply chain, sales force expansion, and reimbursement alignment are critical operational levers

Risks

  • Elevated cash burn and the need to access capital markets, which could cause dilution or unfavorable financing terms
  • Slower-than-expected commercial adoption of new implants or surgical techniques, reducing revenue and margin expansion
  • Regulatory or clinical setbacks affecting product approvals or labeling that would impair market access
  • Intense competition from larger device makers with broader hospital relationships and deeper reimbursement teams
  • Procedure-volume sensitivity (elective-surgery cycles, hospital budgets) that can amplify revenue volatility
  • Low trading liquidity and high share-price volatility increasing downside risk during negative newsflow

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ATEC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.